Online Only Articles

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma

Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
BeiGene LTD, Beijing, China
BeiGene LTD, Beijing, China
BeiGene LTD, Beijing, China
Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
BeiGene LTD, Beijing, China
Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia;Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia;Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia;Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia;Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia;The ACRF Translational Research Laboratory; Royal Melbourne Hospital, Parkville, Victoria, Australia
Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia;The ACRF Translational Research Laboratory; Royal Melbourne Hospital, Parkville, Victoria, Australia
Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
BeiGene LTD, Beijing, China
Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia;Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
Vol. 105 No. 2 (2020): February, 2020 https://doi.org/10.3324/haematol.2019.220590